BTAI vs MCK · rev $388.0K vs P/E 20, rev $403.43B
BioXcel Therapeutics Inc (BTAI) versus McKesson Corporation (MCK) — a side-by-side from cached financials, not a winner call.
BioXcel Therapeutics Inc (BTAI) is a drug manufacturers - specialty & generic company listed on US.
McKesson Corporation (MCK) is a medical distribution company listed on NYSE.
Latest reported BTAI revenue for 2026-06-30 was $388.0K. Net income was -$27.4M. Revenue was up 88.3% from 2026-03-31 to 2026-06-30. BTAI currently screens at market cap $36.1M.
Latest reported MCK revenue for 2026-03-31 was $403.43B. Net income was $4.76B. Revenue was up 12.4% from 2025-03-31 to 2026-03-31. MCK currently screens at market cap $91.30B and trailing P/E 20.3.
BTAI currently screens at market cap $36.1M. MCK currently screens at market cap $91.30B and trailing P/E 20.3.
Not investment advice. Open the BTAI and MCK stock pages for the full models.
Not investment advice.